Evaluation of TNF-α inhibitors in stage 2 T1D also represents a potential path for moving TNF-α inhibitors to the clinical setting and may even support testing TNF-α inhibitors in combination with other approved DMTs. The gene discussed is TNF; the disease is type 1 diabetes mellitus.